Cite

HARVARD Citation

    Guerrero, J. et al. (2013). Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration‐resistant prostate cancer. Prostate. 73 (12), pp. 1291-1305. [Online]. 
  
Back to record